Category

Archives

MDM2/MDMX

Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma

19 views | Jul 31 2022

Ken Ito et al. found that the combination of nutlin-3 with chemotherapeutic agents might become a novel therapeutic strategy in esophageal cancer over-expressing MDM2. [Read the Full Post]

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup

28 views | Jul 29 2022

Angela Martinez-Monleon et al. presented detailed biological data of an aggressive neuroblastoma subgroup hallmarked by 12q amplification and atypical clinical presentation for which in vitro studies indicated that CDK4 and/or MDM2 inhibition also could be beneficial. [Read the Full Post]

Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes

19 views | Jul 22 2022

Qianqian Wang et al. identified MDM2 as an essential gene and a potential therapeutic target in wtTP53-RTK NSCLC via a genome-wide CRISPR/Cas9 screening. [Read the Full Post]

Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells

171 views | Jan 11 2022

Min Lu et al. thought that treatment with ONC201 combined with RG7112 could be a potentially effective strategy for treating MF patients. [Read the Full Post]

The balance between p53 isoforms modulates the efficiency of HIV-1 infection in macrophages

353 views | Sep 06 2021

Yann Breton et al. demonstrated the involvement of p53 isoforms, which regulated p53 activity and defined the cellular environment influencing viral replication. [Read the Full Post]

P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma

355 views | Sep 05 2021

Yohei Sekino et al. thought that p53 might be involved in sunitinib resistance and represent a valuable marker for sunitinib treatment in mRCC. [Read the Full Post]

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors

231 views | Aug 29 2021

Antoine Italiano et al. demonstrated dose- and schedule-dependent p53 activation with durable disease stabilization in some patients. [Read the Full Post]

MDM2 inhibition: an important step forward in cancer therapy

398 views | Jan 21 2021

Marina Konopleva et al. thought that targeting MDM2 was a promising treatment strategy. [Read the Full Post]

Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics

456 views | Aug 20 2020

Wangxiao He et al. proposed that this clinically viable drug delivery strategy could be applied not only to peptide activators of p53 for cancer therapy, but also to peptide therapeutics in general aimed at targeting intracellular protein-protein interactions for disease intervention. [Read the Full Post]

F-box protein FBXO31 modulates apoptosis and epithelial-mesenchymal transition of cervical cancer via inactivation of the PI3K/AKT-mediated MDM2/p53 axis

359 views | Aug 19 2020

Keying Liu et al. revealed that FBXO31 down-regulated CC progression by blocking the PI3K/AKT-mediated MDM2/p53 axis, suggesting that FBXO31 might serve as a promising therapeutic target for CC treatment. [Read the Full Post]